ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)
NCT: NCT05388708 · ACTIVE_NOT_RECRUITING
Brief Summary
ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives. The first objective is to learn more about children's abilities and quality of life among ECMO-supported children in the year after they leave the pediatric intensive care unit. The second objective is to compare short and long-term patient outcomes in two groups of children: one group managed with a mechanical ventilation protocol that reserves the use of extracorporeal membrane oxygenation (ECMO) until protocol failure to another group supported on ECMO per usual care.
Frequently Asked Questions
What is ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)?
ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND) is a clinical trial registered under NCT05388708. Current status: ACTIVE_NOT_RECRUITING.
What is the status of NCT05388708?
The current status of NCT05388708 (ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)) is: ACTIVE_NOT_RECRUITING.
When did ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND) start?
ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND) started on 2021-02-04.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.